Is the cellular uptake of respiratory aerosols delivered from different devices equivalent?

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 93, Issue , 2015, Pages 320-327

  Ong, Hui Xin ^a,b   Traini, Daniela ^a,b   Loo, Ching Yee ^a   Sarkissian, Lala ^a,b   Lauretani, Gianluca ^a,c   Scalia, Santo ^c   Young, Paul M ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF FERRARA   (Italy)

Author keywords

Andersen cascade impactor; Calu 3; DPI; Inhaled formulation; Nebuliser; pMDI; Salbutamol

Indexed keywords

SALBUTAMOL; AEROSOL; BRONCHODILATING AGENT; POWDER;

AEROSOL; ANDERSEN CASCADE IMPACTOR; ARTICLE; CELL CULTURE; DRUG ABSORPTION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRY POWDER INHALER; ELECTRIC RESISTANCE; FLOW RATE; FLOWMETER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; JET NEBULIZER; LUNG ALVEOLUS CELL; MEDICAL DEVICE; MEDICAL NEBULIZER; METERED DOSE INHALER; MORPHOLOGY; PARTICLE SIZE; RESPIRATORY TRACT DISEASE; SCANNING ELECTRON MICROSCOPE; SCANNING ELECTRON MICROSCOPY; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; TRANSEPITHELIAL TRANSPORT; CELL LINE; CHEMISTRY; COMPARATIVE STUDY; CULTURE TECHNIQUE; EPITHELIUM CELL; EQUIPMENT DESIGN; INHALATIONAL DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; METABOLISM; PHARMACEUTICS; POWDER; PROCEDURES; REPRODUCIBILITY; RESPIRATORY TRACT MUCOSA; VALIDATION STUDY;

ADMINISTRATION, INHALATION; AEROSOLS; ALBUTEROL; BRONCHODILATOR AGENTS; CELL CULTURE TECHNIQUES; CELL LINE; CHEMISTRY, PHARMACEUTICAL; DRY POWDER INHALERS; EPITHELIAL CELLS; EQUIPMENT DESIGN; HUMANS; METERED DOSE INHALERS; PARTICLE SIZE; POWDERS; REPRODUCIBILITY OF RESULTS; RESPIRATORY MUCOSA; TECHNOLOGY, PHARMACEUTICAL;

EID: 84930193182     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2015.04.012     Document Type: Article

References (44)

1. J. Fiegel, C. Ehrhardt, U.F. Schaefer, C.-M. Lehr, and J. Hanes Large porous particle impingement on lung epithelial cell monolayers - toward improved particle characterization in the lung Pharm. Res. 20 2003 788 796
2. C.I. Grainger, L.L. Greenwell, D.J. Lockley, G.P. Martin, and B. Forbes Culture of Calu-3 cells at the air interface provides a representative model of the airway epithelial barrier Pharm. Res. 23 2006 1482 1490
3. M. Haghi, H.X. Ong, D. Traini, and P. Young Across the pulmonary epithelial barrier: integration of physicochemical properties and human cell models to study pulmonary drug formulations Pharmacol. Therapeut. 2014
4. H.X. Ong, D. Traini, and P.M. Young Pharmaceutical applications of the Calu-3 lung epithelia cell line Expert Opin. Drug Deliv. 10 2013 1287 1302
5. M. Haghi, D. Traini, M. Bebawy, and P.M. Young Deposition, diffusion and transport mechanism of dry powder microparticulate salbutamol, at the respiratory epithelia Mol. Pharm. 9 2012 1717 1726
6. H.X. Ong, D. Traini, M. Bebawy, and P.M. Young Epithelial profiling of antibiotic controlled release respiratory formulations Pharm. Res. 28 2011 2327 2338
7. H.X. Ong, D. Traini, R. Salama, S.D. Anderson, E. Daviskas, and P.M. Young The effects of mannitol on the transport of ciprofloxacin across respiratory epithelia Mol. Pharm. 10 2013 2915 2924
8. H.X. Ong, D. Traini, D. Cipolla, I. Gonda, M. Bebawy, H. Agus, and P.M. Young Liposomal nanoparticles control the uptake of ciprofloxacin across respiratory epithelia Pharm. Res. 29 2012 3335 3346
9. M. Haghi, M. Bebawy, P. Colombo, B. Forbes, D. Lewis, R. Salama, D. Traini, and P. Young Towards the bioequivalence of pressurised metered dose inhalers 2. Aerodynamically equivalent particles (with and without glycerol) exhibit different biopharmaceutical profiles in vitro Eur. J. Pharm. Biopharm. 86 2014 38 45
10. M. Haghi, D. Traini, and P. Young In vitro cell integrated impactor deposition methodology for the study of aerodynamically relevant size fractions from commercial pressurised metered dose inhalers Pharm. Res. 2014 1 9
11. Office OdS. British Pharmacopoeia, Appendix XII C. 2012; < http://www.pharmacopoeia.co.uk > (accessed 02.02.15).
12. M.E. Abdelrahim Aerodynamic characteristics of nebulized terbutaline sulphate using the andersen cascade impactor compared to the Next Generation Impactor Pharm. Dev. Technol. 16 2011 137 145
13. H. Mohammed, D.L. Roberts, M. Copley, M. Hammond, S.C. Nichols, and J.P. Mitchell Effect of sampling volume on dry powder inhaler (DPI)-emitted aerosol aerodynamic particle size distributions (APSDs) measured by the Next-Generation Pharmaceutical Impactor (NGI) and the Andersen Eight-Stage Cascade Impactor (ACI) AAPS Pharm. Sci. Tech. 13 2012 875 882
14. W. Wong, J. Crapper, H.-K. Chan, D. Traini, and P.M. Young Pharmacopeial methodologies for determining aerodynamic mass distributions of ultra-high dose inhaler medicines J. Pharmaceut. Biomed. 51 2010 853 857
15. S. Nichols Calibration and mensuration issues for the standard and modified impactor Pharmeuropa 14 2000 585
16. H.X. Ong, D. Traini, G. Ballerin, L. Morgan, L. Buddle, S. Scalia, and P.M. Young Combined inhaled salbutamol and mannitol therapy for mucus hyper-secretion in pulmonary diseases AAPS J. 16 2014 269 280
17. Administration FaD. Guidance for Industry; Dissolution Testing of Immediate Release Solid Oral Dosage Forms, August 1997.
18. J.W. Moore, and H.H. Flanner Mathematical comparison of dissolution profiles Pharm. Technol. 20 1996 64 74
19. Administration FaD. Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, 2000.
20. S.P. Newman, and H.K. Chan In vitro/in vivo comparisons in pulmonary drug delivery J. Aerosol Med. Pulm. Drug Deliv. 21 2008 77 84
21. T.C. Carvalho, J.I. Peters, and R.O. Williams Iii Influence of particle size on regional lung deposition - what evidence is there? Int. J. Pharm. 406 2011 1 10
22. W.T.J. Kwong, S.L. Ho, and A.L. Coates Comparison of nebulized particle size distribution with Malvern laser diffraction analyzer versus andersen cascade impactor and low-flow marple personal cascade impactor J. Aerosol Med. 13 2000 303 314
23. Y. Zhou, A. Ahuja, C.M. Irvin, D. Kracko, J.D. McDonald, and Y.S. Cheng Evaluation of nebulizer performance under various humidity conditions J. Aerosol Med. 18 2005 283 293
24. R. Kotian, J. Peart, J. Bryner, and P.R. Byron Calibration of the modified electrical low-pressure impactor (ELPI) for use with pressurized pharmaceutical aerosols J. Aerosol Med. Pulm. Drug Deliv. 22 2009 55 66
25. W.P. Adams, S.L. Lee, R. Plourde, R.A. Lionberger, C.M. Bertha, W.H. Doub, J.-M. Bovet, and A.J. Hickey Effects of device and formulation on in vitro performance of dry powder inhalers AAPS J. 14 2012 400 409
26. C. Van Holsbeke, J. Marshall, J. De Backer, and W. Vos Median mass aerodynamic diameter (MMAD) and fine particle fraction (FPF): influence on lung deposition? Eur. Respir. J. 2014 44
27. O.S. Usmani, M.F. Biddiscombe, and P.J. Barnes Regional lung deposition and bronchodilator response as a function of β2-agonist particle size Am. J. Respir. Crit. Care Med. 172 2005 1497 1504
28. R.A. Lewis, and J.S. Fleming Fractional deposition from a jet nebulizer: how it differs from a metered dose inhaler Brit. J. Dis. Chest. 79 1985 361 367
29. B. Zainudin, M. Biddiscombe, S. Tolfree, M. Short, and S. Spiro Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurised metered dose inhaler, as a dry powder, and as a nebulised solution Thorax 45 1990 469 473
30. S.P. Newman, D. Pavia, F. Morén, N. Sheahan, and S.W. Clarke Deposition of pressurised aerosols in the human respiratory tract Thorax 36 1981 52 55
31. S. Newman, G. Pitcairn, K. Steed, A. Harrison, and J. Nagel Deposition of fenoterol from pressurized metered dose inhalers containing hydrofluoroalkanes J. Allergy Clin. Immunol. 104 1999 s253 s257
32. S.P. Newman, A. Hollingworth, and A.R. Clark Effect of different modes of inhalation on drug delivery from a dry powder inhaler Int. J. Pharm. 102 1994 127 132
33. D.M. Newnham, and B.J. Lipworth Nebuliser performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system ("Ventstream") Thorax 49 1994 762 770
34. D. Clark, and B. Lipworth Lung bioavailability of chlorofluorocarbon free, dry powder and chlorofluorocarbon containing formulations of salbutamol Br. J. Clin. Pharmacol. 41 1996 247 249
35. B. Lipworth, and D. Clark Comparative lung delivery of salbutamol given via Turbuhaler and Diskus dry powder inhaler devices Eur. J. Clin. Pharmacol. 53 1997 47 49
36. D. Newnham, D. McDevitt, and B. Lipworth Comparison of the extrapulmonary β2-adrenoceptor responses and pharmacokinetics of salbutamol given by standard metered dose-inhaler and modified actuator device Br. J. Clin. Pharmacol. 36 1993 445 450
37. H.-J. Tong, C. Fitzgerald, P. Gallimore, M. Kalberer, M. Kuimova, P. Seville, A. Ward, and F. Pope Rapid interrogation of the physical and chemical characteristics of salbutamol sulphate aerosol from a pressurised metered-dose inhaler (pMDI) Chem. Commun. 50 2014 15499 15502
38. C. Grainger, L. Greenwell, G. Martin, and B. Forbes The permeability of large molecular weight solutes following particle delivery to air-interfaced cells that model the respiratory mucosa Eur. J. Pharm. Biopharm. 71 2009 318 324
39. D. Duncan, I. Paterson, D. Harris, and G. Crompton Comparison of the bronchodilator effects of salbutamol inhaled as a dry powder and by conventional pressurised aerosol Br. J. Clin. Pharmacol. 4 1977 669 671
40. J. Hartley, S. Nogrady, and A. Seaton Long-term comparison of salbutamol powder with salbutamol aerosol in asthmatic out-patients Brit. J. Dis. Chest. 73 1979 271 276
41. J.P. Kemp, M.R. Hill, L.M. Vaughan, E.O. Meltzer, M.J. Welch, and N.K. Ostrom Pilot study of bronchodilator response to inhaled albuterol delivered by metered-dose inhaler and a novel dry powder inhaler Ann. Allergy Asthma Immunol. 79 1997 322 326
42. B. Lipworth, and D. Clark Lung delivery of non-CFC salbutamol via small volume metal spacer and large volume plastic spacer devices compared with an open vent jet nebulizer Br. J. Clin. Pharmacol. 45 1998 160 163
43. P.J. Poole, R. Saini, S.M. Brodie, and P.N. Black Comparison of the effects of nebulised and inhaled salbutamol on breathlessness in severe COPD Resp. Med. 99 2005 372 376
44. V. Joguparthi, P. Breen, C. Compadre, X. Zhou, L. Gann, F.C. Hiller, and P. Anderson Effect of propellant on the pharmacokinetics and pharmacodynamics of inhaled albuterol in asthmatic subjects J. Aerosol Med. 16 2003 47 53